NYU Langone Insights on Psychiatry

NYU Langone Health Department of Psychiatry
  • 4.8 (20)
  • LIFE SCIENCES
  • UPDATED WEEKLY

Conversations about complex psychiatric cases and evolving treatments. Host Charles Marmar, MD, Chair of Psychiatry at NYU Grossman School of Medicine, speaks with NYU Langone faculty about diagnostic reasoning, treatment decisions, and the ethical questions that arise in clinical practice.

  1. Closing the Revolving Door of Severe Mental Illness

    1D AGO

    Closing the Revolving Door of Severe Mental Illness

    Bipin Subedi, MD, explores how health systems can better care for patients with severe mental illness who cycle between hospitals, homelessness, addiction, and the justice system. He argues that acute inpatient treatment, while essential, is rarely sufficient on its own. Preventing the revolving door of repeated hospitalizations requires psychiatry to extend beyond hospital walls and build integrated systems that follow patients into the community. Drawing on his leadership at NYU Bellevue and his background in forensic psychiatry, Dr. Subedi describes a model of care built on sustained relationships, flexibility, and continuity. He reflects on how programs like transitional housing and mobile post-discharge support can provide the “scaffolding” patients need when insight and executive function are impaired by psychosis. The conversation closes with practical guidance on strengthening medication adherence—particularly through thoughtful use of long-acting injectables—and on meeting patients where they are to advance more humane, effective care. Bipin Subedi, MD, is Associate Professor of Psychiatry at NYU Grossman School of Medicine and Chief of Psychiatry at NYU Bellevue Hospital. He is a forensic psychiatrist with prior leadership experience in New York City’s jail system. ▶️ Watch Insights on Psychiatry on YouTube 01:36 Bellevue’s Mission and Rising Clinical Complexity 04:43 Extending Care Beyond the Hospital Walls 05:15 Bridge to Home and Transitional Stabilization 10:44 Forensic Psychiatry and the Justice System 14:17 Psychosis and Impaired Insight 15:53 Post-Discharge Scaffolding and Critical Time Intervention 18:47 Preventing Relapse with Long-Acting Injectables 22:36 Meeting Patients Where They Are This episode is intended for psychiatrists, mental health clinicians, and health system leaders interested in serious mental illness and innovative models of integrated community care. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

    24 min
  2. Diagnosing Autoimmune Psychosis

    FEB 9

    Diagnosing Autoimmune Psychosis

    Katlyn Nemani, MD, explores how autoimmune and inflammatory brain disorders can present as first-episode psychosis—and why some patients diagnosed with schizophrenia may actually have a treatable immune-mediated illness. She explains the clinical features that should prompt suspicion for autoimmune psychosis, including subacute onset, subtle neurologic signs, and poor response to antipsychotics, even when standard imaging and antibody tests are unrevealing. Dr. Nemani also discusses the limits of current biomarkers, how to think clinically when diagnostic certainty is incomplete, and why early immunotherapy can dramatically alter outcomes. The conversation closes with a forward-looking discussion of emerging research suggesting that a meaningful subset of schizophrenia-like illness may ultimately be reclassified as autoimmune in origin. Katlyn Nemani, MD, is a Research Assistant Professor in the Departments of Psychiatry and Neurology at NYU Grossman School of Medicine and a graduate of NYU’s combined Neurology-Psychiatry residency program. ▶️ Watch Insights on Psychiatry on YouTube 00:00 When Psychosis May Be an Autoimmune Disease 01:18 Early Psychiatric Symptoms of Autoimmune Encephalitis 02:47 Why Subtle Neurologic Clues Matter 04:00 A Case of Rapidly Reversible Psychosis 06:37 The Limits of Antibody Testing 07:51 Why Early Treatment Changes Outcomes 08:18 Rethinking the Heterogeneity of Schizophrenia 09:31 How Common Is Autoimmune Contribution to Psychosis? 10:48 Network-Level Brain Effects and Open Research Questions This episode is intended for psychiatrists, neurologists, and other clinicians interested in psychosis, neuroinflammation, and complex diagnostic presentations at the psychiatry–neurology interface. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

    12 min
  3. The Neuropsychiatry of Complex Brain Injury Care

    FEB 2

    The Neuropsychiatry of Complex Brain Injury Care

    Lindsey Gurin, MD, discusses how clinicians can approach patients whose symptoms fall at the intersection of psychiatry and neurology. Drawing on her work with traumatic brain injury, PTSD, and persistent post-concussive symptoms, she explains why attempts to separate psychological trauma from neurological injury often obscure what patients actually need. The conversation explores identity disruption after brain injury, the unintended effects of rigid recovery timelines, and the importance of continuity in understanding symptoms over time. Dr. Gurin also discusses how neurodevelopmental traits such as ADHD shape vulnerability and treatment response, when stimulant medications can be appropriate after concussion, and why breaking complex presentations into treatable components often matters more than assigning a single diagnosis. Lindsey Gurin, MD, is Assistant Professor in the Departments of Neurology, Psychiatry, and Rehabilitation Medicine at NYU Langone Health, and Director of the Neurology/Psychiatry Residency Program. ▶️ Watch Insights on Psychiatry on YouTube 00:00 Brain Injury and Identity 01:27 What Is the Psychiatry–Neurology Double Board? 02:41 Why PTSD and TBI Overlap 03:28 What “Shell Shock” Really Means 06:00 When Concussion Symptoms Don’t Go Away 07:25 Life Before vs After Brain Injury 08:46 ADHD as a Hidden Risk Factor 10:28 Using Stimulants After Brain Injury 12:40 Rethinking “Post-Concussion Syndrome” 13:27 The Future of Neuropsychiatric Care This episode is intended for psychiatrists and other clinicians caring for patients with complex neuropsychiatric presentations at the intersection of psychiatry and neurology. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

    18 min
  4. Psychedelics for Treatment-Resistant Disorders

    JAN 26

    Psychedelics for Treatment-Resistant Disorders

    Michael Bogenschutz, MD, explains how psychedelic-assisted treatments may offer new options for patients with severe, treatment-refractory psychiatric conditions. He discusses why standard approaches often fall short for complex cases, how psychedelics like psilocybin and MDMA differ from conventional medications, and what careful screening and clinical structure make these treatments safe and effective. Drawing on randomized clinical trials and years of clinical experience, Dr. Bogenschutz describes how psychedelic treatments can produce durable symptom improvement in disorders such as alcohol use disorder and trauma-related conditions. He also explores unresolved scientific questions, including whether the psychedelic experience itself is necessary for therapeutic benefit. Michael Bogenschutz, MD, is Professor of Psychiatry and Director of the Center for Psychedelic Medicine at NYU Langone Health. ▶️ Watch Insights on Psychiatry on YouTube 00:00 A Remarkable Case: Sustained Sobriety After Psilocybin Treatment 00:39 Introducing Dr. Michael Bogenschutz 01:04 Why Psychiatry Is Re-Examining Psychedelics 02:50 Safety, Screening, and Managing the Psychedelic Experience 03:45 Landmark Trial: Psilocybin for Alcohol Use Disorder 06:16 How Psychedelics Work: Neuroplasticity vs. Subjective Experience 08:53 Can Non-Psychedelic Analogs Deliver the Same Benefits? 11:47 MDMA, Fear Reduction, and Emotional Processing 13:44 Who Benefits Most? A Composite of Treatment-Refractory Patients 15:45 The Future of Psychedelic Psychiatry at NYU This episode is intended for psychiatrists, mental health clinicians, and others interested in complex and treatment-resistant psychiatric conditions. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

    16 min
  5. Treating ADHD in Patients With Bipolar Disorder and Substance Use

    JAN 19

    Treating ADHD in Patients With Bipolar Disorder and Substance Use

    Lenard Adler, MD, explains how clinicians can safely and effectively treat ADHD when bipolar disorder and addiction are also in the picture. He addresses how to distinguish chronic ADHD symptoms from episodic mood disorders, why bipolar disorder is often missed in adults referred for depression or attention problems, and how substance use complicates both diagnosis and medication selection. Dr. Adler also shares guidance on identifying red flags for diversion or misuse, setting appropriate expectations for medication trials, and navigating the limits of current treatment guidelines. The episode closes with a look toward emerging directions in ADHD treatment, including research on emotional dysregulation, executive function deficits, and next-generation neurofeedback approaches. Lenard Adler, MD, is Pottash Professor of Psychiatry and Director of the Adult ADHD Program at NYU Langone Health ▶️ Watch Insights on Psychiatry on YouTube 00:00 Why ADHD, Bipolar Disorder, and Addiction Must Be Treated Together 01:02 What Makes These ADHD Cases So Difficult 02:05 ADHD vs. Bipolar Disorder: Key Diagnostic Distinctions 04:43 The Link Between ADHD and Addiction 05:53 Using Stimulants Safely When Substance Use Is a Concern 07:57 Choosing Stimulants vs. Non-Stimulants 10:07 How Severity and Comorbidity Shape Treatment Decisions 12:06 The Limits of Guidelines and Biomarkers in ADHD Care 15:34 Executive Function and Emotional Dysregulation 16:13 Where ADHD Treatment Is Headed Next This episode is intended for psychiatrists, mental health clinicians, and others interested in complex adult ADHD presentations. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

    21 min
  6. Delivering Addiction Care Outside Traditional Settings

    JAN 12

    Delivering Addiction Care Outside Traditional Settings

    Ayana Jordan, MD, PhD, discusses how precision psychiatry must expand beyond biology to address the social, cultural, and structural realities shaping addiction and mental health care for historically underrepresented patients. The conversation explores how trauma, poverty, housing instability, health literacy, and stigma interact with substance use and serious mental illness—and why traditional clinic-based models often fail to meet patients where they are. Dr. Jordan describes the work of the Jordan Wellness Collaborative, including partnerships that integrate addiction treatment into primary care, community settings, and faith-based institutions. She explains how peer facilitators, housing support, and trusted community spaces can dramatically improve engagement, retention, and outcomes. Looking ahead, she reflects on how emerging tools—from AI-supported care models to novel treatments for addiction—may further transform access and equity in psychiatric care. Ayana Jordan, MD, PhD, is the Barbara Wilson Professor of Psychiatry at NYU Grossman School of Medicine and Principal Investigator of the Jordan Wellness Collaborative. ▶️ Watch Insights on Psychiatry on YouTube TOPICS Expanding precision psychiatry beyond biological modelsStructural barriers to care: housing, literacy, and stigmaAddiction treatment for historically underrepresented communitiesIntegrating care into primary care, community, and faith-based settingsThe role of peer facilitators and lived experience in treatmentTrust, safety, and engagement for patients with complex needsFuture directions: AI, novel addiction treatments, and workforce training This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

    17 min
  7. Bipolar Depression and Mixed Episodes: Rethinking Treatment Goals

    JAN 2

    Bipolar Depression and Mixed Episodes: Rethinking Treatment Goals

    Dan Iosifescu, MD, discusses why bipolar depression and mixed episodes remain among the most difficult—and highest-risk—conditions in psychiatry. Even when mood symptoms improve, many patients continue to experience significant cognitive and functional impairment. Dr. Iosifescu argues that standard approaches often fall short because symptom suppression is mistaken for recovery, short-term improvement is confused with durable treatment, and mixed episodes expose the limits of one-size-fits-all care. The conversation explores the clinical dangers of mixed episodes, the challenge of recognizing them, and the importance of moving deliberately from acute stabilization to sustainable long-term treatment.  Dan Iosifescu, MD, is Director of Clinical Research at the Nathan Kline Institute and Director of the Mood Disorders Clinical and Research Program at NYU Langone Health. ▶️ Watch Insights on Psychiatry on YouTube 00:33 Introduction 01:22 Challenges of Treating Bipolar Depression 02:58 Case Study: The Impact of Bipolar Depression 05:01 Novel Treatments and Approaches 07:23 Understanding and Managing Mixed Episodes 13:44 Future Directions in Bipolar Disorder Treatment 16:09 Innovative Research at NYU Psychiatry 22:33 Conclusion and Final Thoughts This episode is intended for psychiatrists, mental health clinicians, and others interested in treatment-resistant forms of depression and bipolar disorder. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

    23 min
  8. Interventional Approaches to Treatment-Resistant Mood Disorders

    12/26/2025

    Interventional Approaches to Treatment-Resistant Mood Disorders

    Joshua Berman, MD, PhD, discusses how careful evaluation, patient priorities, and risk-benefit tradeoffs guide the use of interventional treatments when conventional approaches fall short. Dr. Berman also explains how tools such as ketamine, TMS, ECT, and neurofeedback can be used strategically—sometimes in sequence or combination—to address different vulnerabilities within mood-related brain circuits. Dr. Berman is Associate Professor of Psychiatry and Director of Interventional Psychiatry at NYU Langone Health. ▶️ Watch Insights on Psychiatry on YouTube 00:47 What Is Interventional Psychiatry? 02:33 Evaluating Treatment-Resistant Presentations 06:31 Precision, Patient Priorities, and Clinical Judgment 09:35 Sequencing and Combining Interventions 10:40 Limits of Treatment Guidelines 12:18 The Future of Interventional Psychiatry 13:23 Emerging Technologies: Neurofeedback and Focused Ultrasound 17:15 Building a Comprehensive Interventional Program 18:13 Tools vs. Understanding Brain Circuits This episode is intended for psychiatrists, mental health clinicians, and others interested in interventional approaches to complex psychiatric disorders. This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care. Senior Producer: Jon Earle

    19 min
See All (42)

4.8
out of 5
20 Ratings

About

Conversations about complex psychiatric cases and evolving treatments. Host Charles Marmar, MD, Chair of Psychiatry at NYU Grossman School of Medicine, speaks with NYU Langone faculty about diagnostic reasoning, treatment decisions, and the ethical questions that arise in clinical practice.

Information

  • Creator
    NYU Langone Health Department of Psychiatry
  • Years Active
    2023 - 2026
  • Episodes
    42
  • Rating
    Clean
  • Copyright
    © 2026 NYU Langone Health
  • Show Website
    NYU Langone Insights on Psychiatry

You Might Also Like